1. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. Issue 3 (December 2015) Authors: Schmid-Bindert, Gerald; Engel-Riedel, Walburga; Reck, Martin; Schuette, Wolfgang; Stöhlmacher, Jan; Fischer, Jürgen R.; Mazières, Julien; Chouaid, Christos; Wolf, Martin; Vinolas, Nuria; Soldatenkova, Victoria; Ripoche, Veronique; Nguyen, Tuan; Visseren-Grul, Carla Journal: Lung cancer Issue: Volume 90:Issue 3(2015:Dec.) Page Start: 397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer. Issue 1 (27th February 2018) Authors: Engel-Riedel, Walburga; Lowe, Jamie; Mattson, Paulette; Richard Trout, J.; Huhn, Richard D.; Gargano, Michele; Patchen, Myra L.; Walsh, Richard; Trinh, My My; Dupuis, Mariève; Schneller, Folker Journal: Journal for immunotherapy of cancer Issue: Volume 6:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Combination of Pyrosequencing® and Sanger sequencing reveals alleged novel mutation in exon 18 of EGFR. (March 2013) Authors: Schildgen, Verena; Schulz, Carolin; Lüsebrink, Jessica; Tillmann, Ramona-Liza; Engel-Riedel, Walburga; Stoelben, Erich; Schildgen, Oliver; Brockmann, Michael Journal: Personalized medicine Issue: Volume 10:Number 2(2013) Page Start: 201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Combined point mutation in KRAS or EGFR genes and EML4–ALK translocation in lung cancer patients. (March 2014) Authors: Jürgens, Jessica; Engel-Riedel, Walburga; Prickartz, Alexander; Ludwig, Corinna; Schildgen, Oliver; Tillmann, Ramona-Liza; Stoelben, Erich; Brockmann, Michael; Schildgen, Verena Journal: Future oncology Issue: Volume 10:Number 4(2014) Page Start: 529 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Combined point mutation in KRAS or EGFR genes and EML4–ALK translocation in lung cancer patients. (March 2014) Authors: Jürgens, Jessica; Engel-Riedel, Walburga; Prickartz, Alexander; Ludwig, Corinna; Schildgen, Oliver; Tillmann, Ramona-Liza; Stoelben, Erich; Brockmann, Michael; Schildgen, Verena Journal: Future oncology Issue: Volume 10:Number 4(2014) Page Start: 529 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). Issue 2 (May 2015) Authors: Garrido, Pilar; Engel-Riedel, Walburga; Serke, Monika; Giraud, Philippe; Ricardi, Umberto; Vallejo, Carmen; Visseren-Grul, Carla; Ameryckx, Sophie; Soldatenkova, Victoria; Chouaki, Nadia; Novello, Silvia Journal: Lung cancer Issue: Volume 88:Issue 2(2015:May) Page Start: 160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance. (May 2018) Authors: Christopoulos, Petros; Schneider, Marc A.; Bozorgmehr, Farastuk; Kuon, Jonas; Engel-Riedel, Walburga; Kollmeier, Jens; Baum, Volker; Muley, Thomas; Schnabel, Philipp A.; Bischoff, Helge; Grohé, Christian; Serke, Monika; Thomas, Michael; Fisch, Paul; Meister, Michael Journal: Lung cancer Issue: Volume 119(2018) Page Start: 48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Issue 1 (December 2018) Authors: Fassunke, Jana; Müller, Fabienne; Keul, Marina; Michels, Sebastian; Dammert, Marcel; Schmitt, Anna; Plenker, Dennis; Lategahn, Jonas; Heydt, Carina; Brägelmann, Johannes; Tumbrink, Hannah; Alber, Yannic; Klein, Sebastian; Heimsoeth, Alena; Dahmen, Ilona; Fischer, Rieke; Scheffler, Matthias; Ihle,... Journal: Nature communications Issue: Volume 9:Issue 1(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 12 (December 2019) Authors: Nakagawa, Kazuhiko; Garon, Edward B; Seto, Takashi; Nishio, Makoto; Ponce Aix, Santiago; Paz-Ares, Luis; Chiu, Chao-Hua; Park, Keunchil; Novello, Silvia; Nadal, Ernest; Imamura, Fumio; Yoh, Kiyotaka; Shih, Jin-Yuan; Au, Kwok Hung; Moro-Sibilot, Denis; Enatsu, Sotaro; Zimmermann, Annamaria; Frimod... Journal: Lancet oncology Issue: Volume 20:Issue 12(2019) Page Start: 1655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗